08329 NEP INTERLONG
- 0.154
- +0.009+6.21%
NEP INTERLONG News
Neptune Interlon (08329.HK) will purchase medical devices from the Neptune Group
Gelonghui, May 7, 丨 Neptune Interlon (08329.HK) announced that the company and Neptune Biotech (the company's controlling shareholder and related party) entered into a 2024 framework agreement on May 7, 2024. Based on this, the Group will purchase medical devices from Haiwang Group to be sold on behalf of China.
NEP INTERLONG: 2023 Annual Report
Neptune Interlon (08329) announced 2023 results. Profit attributable to owners of 24.127 million yuan decreased by 55.6% year-on-year
Neptune Interlon (08329) announced its 2023 results, with revenue of about 1,065 billion yuan, an increase of about 7.9 billion yuan over the previous year...
海王英特龍：截至二零二三年十二月三十一日止年度全年業績公佈
海王英特龍：董事會會議日期延期
Neptune Interlon (08329) Fa Profit Alert expects annual profit attributable to shareholders to be reduced by more than 50%
According to the Zhitong Finance App, Neptune Interlon (08329) announced that it is expected that the profit attributable to company owners obtained by the Group for the year ended December 31, 2023 will be reduced by more than 50% compared to the same period in 2022. The main reason for this reduction was due to impairment losses in goodwill formed when the Group acquired Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.
NEP INTERLONG: INSIDE INFORMATION ANNOUNCEMENT PROFIT WARNING
Neptune Interlon (08329) and Neptune Easy Pharmaceutical signed a distribution agreement for 2023
According to the Zhitong Finance App, Neptune Interlon (08329) issued an announcement regarding the 2020 Neptune Star Consignment Agreement. Since the 2020 Neptune Star Consignment Agreement will expire on December 31, 2023, on December 28, 2023, the company and Neptune (a related party of the company) signed a 2023 consignment agreement. The Group will supply pharmaceuticals, food, health food and medical equipment to Easy Pharmaceutical Group for consignment sales in China. According to reports, these drugs (mainly including antibiotics, psychosomatic drugs, respiratory drugs, anti-allergy drugs and digestive drugs) and medical equipment are managed by the Group
NEP INTERLONG: THIRD QUARTERLY REPORT 2023
Neptune Intron (08329) announced the first three quarter results, profit attributable to owners of 45.56 million yuan, up 26.81% year on year
According to the Zhitong Finance App, Haiwang Intron (08329) announced its results for the first three quarters of 2023, with revenue of approximately RMB 823 million, up 19.41% year on year; profit attributable to company owners of RMB 45.06 million, up 26.81% year on year; earnings per share of 2.71 points.
NEP INTERLONG: ANNOUNCEMENT OF THIRD QUARTERLY RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023
NEP INTERLONG: 2023 INTERIM REPORT
NEP INTERLONG: ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
NEP INTERLONG: NOTICE OF BOARD MEETING
Haiwang Interlong (08329): Shen Dakai retires as non-executive director
According to the Zhitong Finance App, Haiwang Interlong (08329) issued an announcement that Zhang Xiaoguang has been appointed as an executive director, effective from June 25, 2023. Furthermore, due to the work schedule, Shen Dakai did not seek re-election at the company's annual shareholders' meeting, so Shen Dakai's term of office will expire on June 24, 2023, and will retire as a non-executive director thereafter.
Haiwang Intelong (08329) appoints Zhang Xiaoguang as Executive Director
According to the Zhitong Finance App, Haiwang Interlong (08329) issued an announcement with effect from June 25, 2023: re-election of Zhang Feng and Huang Jianbo as executive directors, re-election of Zhang Yifei, Yu Lin and Jin Rui as non-executive directors, and re-election of Yi Yongfa, Pan Jiayang and Zhang Jianzhou as independent non-executive directors. Zhang Xiaoguang was appointed as Executive Director. Xiong Chuxiong and Jin Ge were re-elected as supervisors and Cao Yang was re-elected as employee representative supervisor. Zhang Feng has been elected chairman of the new board of directors for a term of 3 years. Xiong Chuxiong has been elected chairman by the new board of supervisors for a term of 3 years.
Haiwang Interlong (08329.HK): Proposed Appointment of Zhang Xiaoguang as Executive Director
Glonghui, May 18 丨 Haiwang Interlong (08329.HK) announced that due to work arrangements, Shen Dakai has informed the board of directors that he will retire as a non-executive director and will not seek re-election at the company's upcoming annual general meeting of shareholders. According to the recommendation of the company's nomination committee, the board of directors recommended the appointment of Zhang Xiaoguang as an executive director at the annual general meeting of shareholders.
NEP INTERLONG: FIRST QUARTERLY REPORT 2023
Aquaman Interlong (08329.HK)'s revenue for the first quarter was about 300 million yuan, up about 38.95% year-on-year
Glonghui, May 4 丨 Haiwang Interlong (08329.HK) announced that for the three months ending March 31, 2023, the company's revenue was approximately RMB 300 million, an increase of about 38.95% over the same period last year. The gross margin for the reporting period was about 47%, up about 2 percentage points from about 45% in the same period last year. The increase in gross margin compared to last year was mainly due to factors such as the impact of the COVID-19 pandemic and an increase in sales of high-margin varieties during the reporting period. Profit attributable to owners during the company period was approximately RMB 16.264 million, an increase of about 54.29% over the same period last year.
Haiwang Intron (08329) announced first-quarter results. The profit attributable to shareholders of 16.264 million yuan increased 54.29% year-on-year
According to the Zhitong Finance App, Haiwang Interlong (08329) announced results for the 3 months ending March 31, 2023. The group obtained revenue of RMB 300 million (same unit below), an increase of 38.95% over the previous year; company owners should account for a profit of RMB 16.264 million, an increase of 54.29% over the previous year; and a profit of 0.97 points per share. According to the announcement, the Group's gross profit for the reporting period was about 140.8 million yuan, an increase of about 44.35% over the same period last year of about 97.54 million yuan. The increase in gross profit is mainly due to an increase in the Group's overall gross margin and revenue.
Analysis
Price Target
No Data
